DaBlaCa 23 - The European Collaborative Study on Upper Urinary Tract Urothelial Carcinoma

What this Trial Is About

This research investigates upper urinary tract urothelial carcinoma (UTUC), a rare cancer affecting the kidney's pelvis and ureter. The study focuses on comparing current treatments, particularly kidney-sparing surgery versus the standard removal of the kidney and ureter. It aims to determine if more patients with superficial, non-invasive UTUC can safely preserve their kidney without increasing cancer recurrence risk while maintaining quality of life. The study also explores bladder cancer development after UTUC treatment, kidney function changes, and outcomes for patients with Lynch syndrome, a genetic condition linked to UTUC. The study is an observational, multicenter cohort involving patients diagnosed with UTUC confirmed by pathology. It compares groups receiving kidney-sparing surgery, especially those with imperative indications, to those undergoing radical nephroureterectomy, the standard treatment. No experimental treatments are assigned; clinical care follows routine practice. Data is collected at diagnosis and during follow-ups at 1, 3, 5, and 10 years, including quality-of-life questionnaires for Danish patients. Participants provide medical record information and complete quality-of-life surveys. Researchers will assess overall survival, cancer-specific survival, recurrence rates, disease progression, kidney function over time, and patient-reported outcomes. Data is securely collected and managed, with long-term follow-up planned up to 10 years. The study supports improving personalized treatment and refining prediction tools for UTUC outcomes.

The Danish Bladder Cancer Group 23 Study - A European Study on Cancer in the Upper Urinary Tract